Skip to main navigation

Contact Us
Global
- International
- Canada
- France
- Germany
- Italy
- Japan
- Netherlands
- Spain

About Amicus
- About Amicus
- Chairman’s Welcome
- Leadership
- Belief Statement
- Contact Us
- Message from BIO
Patient Advocacy
- Patient Advocacy
- Disease Information
- Rare Stories
- Patient Advisory Boards
- Corporate Giving
- Resources
- Expanded Access
Programs & Pipeline
- Programs & Pipeline
- Our Pipeline
- Fabry Disease
- Pompe Disease
- Batten Disease
- Additional Preclinical Programs
- Clinical Trials
- Platform Technologies
- Journal Articles
- Publications & Posters
Product
- Product
- Galafold^®
- Amicus Assist™
Responsibility
- Responsibility
- Ethics & Compliance
- Global Medical Affairs
- Corporate Giving
- Healing Beyond Disease
- ESG Report
Investors & Media
- Investors & Media
- Investor Relations
- Senior Management Team
- Board of Directors
- Corporate Governance
- Press Releases
- Events & Presentations
- Annual Reports and Proxies
- SEC Filings
- Stock Performance
- Investor FAQs
- Contact Us
- Sign Up for Email Alerts
- Featured Coverage
- Electronic Press Kit
Careers
- Careers
- Overview
- Search

Investors

Press Releases

Press Releases

Year

March 27, 2023

Amicus Therapeutics Announces European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease

March 1, 2023

Amicus Therapeutics Announces Full-Year 2022 Financial Results and Corporate Updates

February 27, 2023

Amicus Therapeutics to Present at the Cowen 43rd Annual Health Care Conference

February 22, 2023

Amicus Therapeutics Announces Positive Long-Term Data from Phase 3 Open-label Extension Study of AT-GAA in Late-Onset Pompe Disease at the 19th Annual WORLDSymposium™ 2023

February 14, 2023

Amicus Therapeutics to Announce Full-Year 2022 Financial Results on March 1, 2023

February 13, 2023

Amicus Therapeutics Announces Presentations and Posters at the 19th Annual WORLDSymposium™ 2023

February 8, 2023

Amicus Therapeutics to Present at the SVB Securities Global Biopharma Conference

January 9, 2023

Amicus Therapeutics Reports Preliminary 2022 Revenue and Provides 2023 Strategic Outlook

January 3, 2023

Amicus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

About Amicus

Patient Advocacy

Programs & Pipeline

Product
- Overview
- Amicus Assist™

Responsibility

Investors & Media

Careers
- Overview
- Search

Social Media
- Twitter
- YouTube
- LinkedIn

Copyright © 2023 Amicus Therapeutics. All rights reserved. NP-AT-ALL-00011119

Cookies Statement
Terms of Use
Privacy Notice
Privacy Shield Policy

The site you are about to enter is intended for US healthcare professionals.

Please confirm you are a US healthcare professional.

I am a US healthcare professional I am not a US healthcare professional